Haemonetics Corp (HAE) company profile
Close on Nov 17, 2026Market cap $5.50BP/E 59.0Yield –
About Haemonetics
Surgical & Medical Instruments & Apparatus, SIC 3841
Haemonetics Corporation is a medical technology provider that supplies devices, software, and consumables to the healthcare sector. The company manages three primary segments: Plasma, Blood Center, and Hospital. Its Plasma division offers automated collection equipment and donor management software for source plasma facilities. The Blood Center unit provides automated apheresis systems to collect and process platelets, plasma, and red cells. Its Hospital segment delivers vascular closure devices, sensor-guided guidewires, esophageal protection tools, diagnostic hemostasis analyzers, surgical cell salvage systems, and transfusion management software. Customers comprise biopharmaceutical companies, blood collection centers, hospitals, group purchasing organizations, and health agencies.
The company sells products in approximately 90 countries via a direct sales force and third-party distributors across about 87 countries. Consumable manufacturing occurs mainly in North America and Malaysia, with contract partners producing components in Japan, Singapore, Thailand, Indonesia, and the Philippines. Equipment production takes place in Malaysia, Australia, and the United States. The text does not identify the company's corporate headquarters.
Summary of the business section of Haemonetics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Haemonetics Corp
- Founded
- 1971
- Headquarters
- Boston, MA
- Address
- 125 Summer Street 02110
- Phone
- (781) 848-7100
- Website
- www.haemonetics.com
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Massachusetts
- Fiscal year ends
- April 3
- Auditor
- Ernst & Young LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- HAE
- Exchange
- NYSE
- IPO date
- May 10, 1991
- Shares outstanding
- 45M, Jul 31, 2026
- Public float
- $2.23B, Sep 27, 2025
- Filer category
- Large accelerated filer
- Stock splits
- 2-for-1, Dec 3, 2012; 2-for-1, Jan 11, 1993
- SEC CIK
- 313143
- CUSIP
- 405024100
- ISIN
- US4050241003
- FIGI
- BBG000C7TF41
- Share class FIGI
- BBG001S6QB64
- LEI
- 549300ZEL6TXZS6F5F95
- EIN
- 04-2882273
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Simon, Christopher | President & CEO, Director | 444,704 |
| Farris Maryanne Maunsell | VP, Chief Accounting Officer | 5,828 |
| Roy Galvin | EVP, Chief Commercial Officer | 39,805 |
| Laurie A. Miller | SVP, Human Resources | 40,987 |
| Frank Chan | EVP, Chief Operating Officer | 5,401 |
| James DArecca | EVP, Chief Financial Officer | 54,444 |
| Michelle L. Basil | EVP and General Counsel | 68,829 |
| Mark W. Kroll | Director | 27,295 |
| Martin D. Madaus | Director | 2,538 |
| Ellen M. Zane | Director | 21,911 |
| Claire Pomeroy | Director | 19,410 |
| Diane M. Bryant | Director | 9,664 |
| Lloyd Emerson Johnson | Director | 15,471 |
| Robert E. Abernathy | Director | 27,519 |
| Michael J. Coyle | Director | 17,932 |
| Charles J. Dockendorff | Director | 25,041 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2026 | $12.04M | $8.12M | $3.35M | $48 | $65 |
| FY2025 | $10.72M | $1.35M | $2.48M | $63 | $121 |
| FY2024 | $11.55M | $10.18M | $2.80M | $85 | $129 |
| FY2023 | $10.69M | $18.08M | $2.40M | $82 | $137 |
| FY2022 | $8.70M | -$2.35M | $2.87M | $63 | $167 |
| FY2021 | $8.63M | $6.61M | $1.95M | $111 | $175 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2026
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|---|
| Christopher A. Simon President and Chief Executive Officer | $1.10M | – | $7.56M | $1.50M | $1.83M | $43.49K | $12.04M | +12% |
| James C. D'Arecca Executive Vice President, Chief Financial Officer | $603.70K | – | $1.84M | $499.99K | $648.86K | $28.99K | $3.62M | +22% |
| Michelle L. Basil Executive Vice President, General Counsel | $558.78K | – | $1.75M | $474.98K | $599.77K | $26.73K | $3.41M | +22% |
| Frank W. Chan Executive Vice President, Chief Operating Officer | $518.26K | $350.00K | $1.47M | $400.00K | $574.06K | $21.39K | $3.34M | – |
| Roy Galvin Executive Vice President, Chief Commercial Officer | $550.21K | – | $1.47M | $400.00K | $586.96K | $28.82K | $3.04M | +38% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Aug 7, 2012 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Feb 19, 2010 | Tender offer | Third-party tender offer for the company's shares |
| Aug 2, 2007 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Apr 17, 1998 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?